JP2007509965A5 - - Google Patents

Info

Publication number

JP2007509965A5

JP2007509965A5 JP2006538281A JP2006538281A JP2007509965A5 JP 2007509965 A5 JP2007509965 A5 JP 2007509965A5 JP 2006538281 A JP2006538281 A JP 2006538281A JP 2006538281 A JP2006538281 A JP 2006538281A JP 2007509965 A5 JP2007509965 A5 JP 2007509965A5

Authority

JP

Japan

Prior art keywords

dosage form

unit dosage

agonist

niacin

inflammatory drug

Prior art date

2004-10-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 12
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 12
• 239000007892 solid unit dosage form Substances 0.000 claims 12
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 11
• 229960003512 nicotinic acid Drugs 0.000 claims 11
• 235000001968 nicotinic acid Nutrition 0.000 claims 11
• 239000011664 nicotinic acid Substances 0.000 claims 11
• 238000000034 method Methods 0.000 claims 10
• 229940084820 Peroxisome proliferator-activated receptor alpha agonist Drugs 0.000 claims 6
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 5
• 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 5
• 229960001138 acetylsalicylic acid Drugs 0.000 claims 5
• 239000000203 mixture Substances 0.000 claims 4
• 239000002356 single layer Substances 0.000 claims 4
• 230000001965 increasing effect Effects 0.000 claims 3
• WSYRBHQWMXTCHQ-SFIKJRKMSA-N (2s)-n-[(2r)-1-[[(2s)-1-[[(2r)-1-[[(2r)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-[[( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 WSYRBHQWMXTCHQ-SFIKJRKMSA-N 0.000 claims 2
• 210000001789 adipocyte Anatomy 0.000 claims 2
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 2
• 229960002297 fenofibrate Drugs 0.000 claims 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
• 230000002195 synergetic effect Effects 0.000 claims 2
• 230000001225 therapeutic effect Effects 0.000 claims 2
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
• 229940123208 Biguanide Drugs 0.000 claims 1
• 208000024172 Cardiovascular disease Diseases 0.000 claims 1
• 208000032928 Dyslipidaemia Diseases 0.000 claims 1
• 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
• 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
• 206010022489 Insulin Resistance Diseases 0.000 claims 1
• 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
• 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
• 239000003153 chemical reaction reagent Substances 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 239000002552 dosage form Substances 0.000 claims 1
• 238000011010 flushing procedure Methods 0.000 claims 1
• 229960001680 ibuprofen Drugs 0.000 claims 1
• 229960000905 indomethacin Drugs 0.000 claims 1
• 229960002009 naproxen Drugs 0.000 claims 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 229960002895 phenylbutazone Drugs 0.000 claims 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 1
• 229960005095 pioglitazone Drugs 0.000 claims 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1